Key Findings:  Looking at safety, tolerability, and preliminary effects this study finds that products containing cannabidiol, cannabigerol, beta-caryophyllene, branched-chain amino acids, or magnesium citrate reduced the delayed onset muscle soreness (DOMS) of performing daily activities, suggesting they may help in post-exercise recovery.
Type of Study:  Double Blind Clinical Trial
Study Sample Size:  40
Study Result:  Positive
Research Location(s):  Canada, United States
Year of Pub:  2023
Cannabinoids Studied:  Cannabidiol (CBD), Cannabigerol (CBG), Endocannabinoid (unspecified)
Phytocannabinoid Source:  Not Applicable
Chemotype:  Chemotype III
Terpenes Studied:  ß-Caryophyllene
DOSING DETAILS   
Study Dosing Objective:  Effective Dose, Safety Profile
Established Protocol:  Effective dose with adverse effects
Cannabinoid Ratio:  (CBD : CBG)   35 : 50    
Dosage Form:  cannabidiol(CBD; 35 mg) cannabigerol (CBG; 50 mg) beta-caryophyllene (BCP; 25 mg) branched-chain amino acids (BCAAs; 3.8 g) magnesium citrate (420 mg)
Dosing Regimen:  Participants consumed the formulation twice per day
Treatment Duration:  3.5 days
Clinical Relevance:  The tested formulation improved function and reduced interference of delayed onset muscle soreness on daily activities.
Adverse Events:  One adverse event in the active group (diarrhea) and two in the placebo (dry mouth; eye rash/swollen eye).
Citation:  Peters EN, et al. A randomized, double-blind, placebo-controlled, repeated-dose pilot study of the safety, tolerability, and preliminary effects of a cannabidiol (CBD)- and cannabigerol (CBG)-based beverage powder to support recovery from delayed onset muscle soreness (DOMS). J Int Soc Sports Nutr. 2023; 20:2280113. doi: 10.1080/15502783.2023.2280113
Authors:  Peters EN, Yardley H, Harrison A, Eglit GML, Antonio J, Turcotte C, Bonn-Miller MO